Free public records show Xgen Pharmaceuticals in 1 of the markets we cover. It is not a key player in our research.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
18 approvals with a product on the US market
Source: Drugs@FDA, Approvals (NDA, ANDA, BLA) held, with a product sold now; newest shown. Retrieved 13 Nov 2026.
7 recalls since 2015 (7 for medicines)
Source: openFDA, FDA enforcement reports (recalls) naming the firm, since 2015. Retrieved 13 Nov 2026.
Markets we cover where free public records show Xgen Pharmaceuticals: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets Xgen Pharmaceuticals is in.
Stories on the topics Xgen Pharmaceuticals works in.
Behind every insurance claim is a standard electronic message. The CAQH Index says $20 billion a year could…
Read
Nearly 15% of US Medicare beneficiaries, 8.2 million people, had a wound or wound infection in one year…
Read
The world has 29.8 million nurses, but still lacks 5.8 million. Training and keeping nurses is a global…
Read